BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 24966582)

  • 1. Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.
    Lonardo A; Adinolfi LE; Restivo L; Ballestri S; Romagnoli D; Baldelli E; Nascimbeni F; Loria P
    World J Gastroenterol; 2014 Jun; 20(23):7089-103. PubMed ID: 24966582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic alterations and hepatitis C: From bench to bedside.
    Chang ML
    World J Gastroenterol; 2016 Jan; 22(4):1461-76. PubMed ID: 26819514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotype 3 Infection: The Last Stand of Hepatitis C Virus.
    Chan A; Patel K; Naggie S
    Drugs; 2017 Feb; 77(2):131-144. PubMed ID: 28074358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic steatosis and hepatitis C: Still unhappy bedfellows?
    Hwang SJ; Lee SD
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():96-101. PubMed ID: 21199519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of genes involved in lipogenesis is not increased in patients with HCV genotype 3 in human liver.
    Ryan MC; Desmond PV; Slavin JL; Congiu M
    J Viral Hepat; 2011 Jan; 18(1):53-60. PubMed ID: 20196803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatitis C virus-associated and metabolic steatosis. Different or overlapping diseases?].
    Lonardo A; Loria P; Adinolfi LE; Andreana A; Ruggiero G; Carulli N
    Ann Ital Med Int; 2005; 20(1):10-22. PubMed ID: 15859390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of HCV Eradication after Direct-Acting Antiviral Agents on Hepatic Steatosis: A Prospective Observational Study.
    Soliman H; Ziada D; Hamisa M; Badawi R; Hawash N; Salama M; Abd-Elsalam S
    Endocr Metab Immune Disord Drug Targets; 2022; 22(1):100-107. PubMed ID: 33550979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocarcinogenesis in hepatitis C: HCV shrewdly exacerbates oxidative stress by modulating both production and scavenging of reactive oxygen species.
    Fujinaga H; Tsutsumi T; Yotsuyanagi H; Moriya K; Koike K
    Oncology; 2011; 81 Suppl 1():11-7. PubMed ID: 22212930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus diversity and hepatic steatosis.
    Roingeard P
    J Viral Hepat; 2013 Feb; 20(2):77-84. PubMed ID: 23301542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of steatosis in hepatitis C virus infection.
    Adinolfi LE; Restivo L; Marrone A
    Expert Rev Gastroenterol Hepatol; 2013 Mar; 7(3):205-13. PubMed ID: 23445230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.
    Adinolfi LE; Rinaldi L; Guerrera B; Restivo L; Marrone A; Giordano M; Zampino R
    Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27231906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small heterodimer partner 1 directly interacts with NS5A viral protein and has a key role in HCV related liver cell transformation.
    Conti B; Porcu C; Viscomi C; Minutolo A; Costantini S; Corazzari M; Iannucci G; Barbaro B; Balsano C
    Oncotarget; 2016 Dec; 7(51):84575-84586. PubMed ID: 27661118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid metabolism and liver disease in hepatitis C viral infection.
    Koike K; Tsutsumi T; Yotsuyanagi H; Moriya K
    Oncology; 2010 Jul; 78 Suppl 1():24-30. PubMed ID: 20616580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transforming Growth Factor β Acts as a Regulatory Molecule for Lipogenic Pathways among Hepatitis C Virus Genotype-Specific Infections.
    Patra T; Sasaki R; Meyer K; Ray RB; Ray R
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Animal models in the study of hepatitis C virus-associated liver pathologies.
    Lerat H; Higgs M; Pawlotsky JM
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):341-52. PubMed ID: 21651352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of HCV genetic differences on pathobiology of disease.
    Ripoli M; Pazienza V
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):747-59. PubMed ID: 21905784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Steatosis and hepatitis C].
    Testino G
    Recenti Prog Med; 2005 Dec; 96(12):621-33; quiz 654. PubMed ID: 16496750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus infection and liver steatosis.
    Ramalho F
    Antiviral Res; 2003 Oct; 60(2):125-7. PubMed ID: 14638408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.
    Rockey DC; Friedman SL
    Gastroenterology; 2021 Apr; 160(5):1502-1520.e1. PubMed ID: 33529675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis.
    Kawagishi N; Suda G; Nakamura A; Kimura M; Maehara O; Suzuki K; Nakamura A; Ohara M; Izumi T; Umemura M; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Kudo Y; Nishida M; Miyoshi H; Sakamoto N
    PLoS One; 2018; 13(12):e0209615. PubMed ID: 30576386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.